QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 vivani-medical-q3-eps-011-inline

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is u...

 vivani-medical-expects-to-spin-off-cortigent-unit-starts-clinical-development-of-npm-139-semaglutide-implant-in-obesity-chronic-weight-management-in-2026

Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniatur...

 vivani-medical-announces-company-presentation-unveils-obesity-market-strategy-with-new-glp-1-implant-technology

https://d1io3yog0oux5.cloudfront.net/_8b0e72ba9731939ad4ef3d445345826e/vivanimedical/db/2227/20875/pdf/Vivani+Corporate+Present...

 vivani-sets-october-8-record-date-for-spin-off-of-cortigent-to-trade-under-nasdaq-ticker-crgt

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only compan...

 vivani-medical-plans-to-initiate-phase-1-clinical-study-in-npm-139-semaglutide-implant-program-in-first-half-of-2026-pending-regulatory-clearance

NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administrationFirst-in-human Phase 1 study is...

 hc-wainwright--co-reiterates-buy-on-vivani-medical-maintains-4-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.

 vivani-medical-q2-eps-012-misses-010-estimate

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0....

 vivani-medical-announces-the-appointment-of-anthony-baldor-as-chief-financial-officer

Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company deve...

 hc-wainwright--co-reiterates-buy-on-vivani-medical-maintains-4-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.

 vivani-medical-q1-eps-011-misses-010-estimate

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0....

 hc-wainwright--co-reiterates-buy-on-vivani-medical-maintains-4-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.

 vivani-medical-expands-collaboration-with-okava-pharmaceuticals-to-include-dogs-in-development-of-okv-119-a-long-acting-glp-1-therapy-for-weight-management-diabetes-and-other-cardiometabolic-conditions

ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or t...

 hc-wainwright--co-reiterates-buy-on-vivani-medical-maintains-4-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION